MBX Company Profile and Key Details

NASDAQ : MBX

MBX Biosciences Common Stock

$43.91

0.88+2.05%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

MBX Biosciences, Inc. Common Stock (MBX) stock surged +2.05%, trading at $43.91 on NASDAQ, up from the previous close of $43.03. The stock opened at $43.54, fluctuating between $43.25 and $46.01 in the recent session.

Stock Snapshot

43.03

Prev. Close

1.48B

Market Cap

43.25

Day Low

-20.24

P/E Ratio

-2.17

EPS (TTM)

N/A

Cash Flow per Share

43.54

Open

33.59M

Number of Shares

46.01

Day High

43.49%

Free Float in %

N/A

Book Value

660.8K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 22, 2026	43.25	46.01	43.25	43.91	660.8K
Jun 18, 2026	42.84	43.49	40.77	43.03	831.97K
Jun 17, 2026	40.12	42.23	39.35	41.59	676.76K
Jun 16, 2026	39.05	42.08	37.84	40.09	1.14M
Jun 15, 2026	35.80	40.00	35.58	38.98	1.26M
Jun 12, 2026	32.00	36.84	32.00	35.51	2.16M
Jun 11, 2026	31.33	37.27	30.51	37.25	2.73M
Jun 10, 2026	29.47	31.15	29.20	30.99	971.31K
Jun 09, 2026	29.68	30.56	28.35	29.87	324.33K
Jun 08, 2026	31.00	31.26	28.00	29.00	739.11K
Jun 05, 2026	30.59	30.69	29.41	30.28	580.36K
Jun 04, 2026	30.07	31.74	29.78	30.91	543.92K
Jun 03, 2026	30.53	30.82	29.55	30.05	454.35K
Jun 01, 2026	31.35	32.03	29.87	30.65	347.8K
May 29, 2026	31.83	32.06	30.80	31.47	821.26K
May 28, 2026	31.80	32.17	31.06	31.90	372.1K
May 27, 2026	31.81	33.06	31.24	31.88	458.15K
May 26, 2026	32.22	32.60	31.08	31.75	247.66K
May 22, 2026	31.91	32.89	31.21	31.85	435.93K
May 21, 2026	31.65	32.39	30.84	31.79	460.32K

Contact Details

Carmel, IN 46032

United States

https://mbxbio.com 317 659 0200

About Company

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

Stock Peers

ARGX

26.03+2.97%

argenx SE$903.75 REGN

2.56+0.42%

Regeneron Pharmaceuticals, Inc.$612.50 UTHR

1.70998+0.32%

United Therapeutics Corporation$538.30 MDGL

7.13+1.41%

Madrigal Pharmaceuticals, Inc.$512.88 VRTX

15.16+3.36%

Vertex Pharmaceuticals Incorporated$466.79 KRYS

-4.63-1.33%

Krystal Biotech, Inc.$343.43 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

21.08+7.47%

Praxis Precision Medicines, Inc.$303.39 ALNY

8.32+2.99%

Alnylam Pharmaceuticals, Inc.$286.41 LGND

-12.71-4.62%

Ligand Pharmaceuticals Incorporated$262.17

Company Overview

MBX Biosciences, Inc. Common Stock (NASDAQ:MBX) closed at $43.91 USD, gaining $0.88 (2.05%) from the previous close of $43.03. The stock is currently within 5% of its 52-week high $9.63 and $46.01. With a market capitalization of about $1.48 billion, MBX Biosciences, Inc. Common Stock is classified as a small-cap and shows lower-than-market volatility (beta ~0.75). Key stats such as the average daily volume over the past year has been around 657.10 thousand shares, in line with its 52-week average. Headquartered in Carmel, IN, MBX Biosciences, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Peter Kent Hawryluk, the company employs approximately 43 people and listed since January 14, 2000. MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions.

Technical Performance

MBX has shown sold momentum, gaining 18.29% over the past week and 226.32% over the past quarter, though year-to-date performance is up 36.78%. Short-term trend indicators are bearishly aligned (SMA20 -6.03%, SMA50 -0.79%, SMA200 66.92%). The stock’s 14-day RSI is 45.7 (neutral), while the ATR of 2.88 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -21.94% below its high and over 628.95% above its low. Average 10-day trading volume of 914.58 thousand shares is slightly above the 3-month average of 673.55 thousand, indicating heightened recent market interest.

Valuation Metrics

MBX Biosciences, Inc. Common Stock trades at a P/E ratio of -20.16, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.72 trading at moderately above to book value. The P/FCF stands at -18.67, also below market averages.

Dividend & Fair Value

MBX Biosciences, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.05. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 14.35% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 1 Sell rating and 0 Strong Sell ratings. Price targets range from $88.00 to $18.00. The high target offers 100.41% upside. The low target suggests -59.01% downside. The mean target is $60.44. This offers 37.65% upside. MBX Biosciences, Inc. Common Stock earnings surprise history is frequent misses against expectations. The quarter that ended May 07, 2026, missed forecasts by -17.74%. The prior quarter beat by -23.44%. Over the last six quarters, Apple has recorded several small beats. These include -20.34% in March 17, 2025.

Shareholding & Insider Activity

MBX Biosciences, Inc. Common Stock has 33.59 million shares outstanding. The public float is 14.61 million shares, elevated short interest at 24.21% of float. This equals 4.07 million shares. The short ratio is 8.19 days. Institutional investors hold 105.45% of the float. Insiders own 2.74%. Heron Patrick J holds 5.22 million shares, Hawryluk P. Kent has 727.67 thousand shares and Pescovitz Ora H. has 24.33 thousand shares. Over the past six months, insider transactions show net selling. They sold 15.84 thousand shares across 3 transactions.

Financial & Profitability Overview

Over the trailing twelve months, MBX Biosciences Common Stock has not generated any revenue.
On valuation metrics, MBX Biosciences Common Stock trades at a P/E of -20.16, P/S of 0.00 and P/B of 4.72. The current ratio is 30.79 and quick ratio is 30.79. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -11363.88 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -139.60.

Price Forecast & Outlook

Our AI price prediction model suggests that MBX Biosciences, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.44%, with price expected at $44.98 by July 06, 2026, within a range of $40.20 to $49.98 3-Month Outlook: Projected rise of 8.54%, reaching $47.66 by September 18, 2026, with a range of $46.32 to $48.97. 1-Year Outlook: Projected gain of 20.63%, with price at $52.97 by June 22, 2027, within a range of $49.86 to $55.59.

Key Takeaways

MBX Biosciences, Inc. Common Stock (NASDAQ:MBX) shares are up 36.78% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows MBX Biosciences, Inc. Common Stock trading at a premium to the broader market with a P/E of -20.16. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $54.45, suggesting 24.0% upside. Our AI forecast model points to short-term strength (2.44% over two weeks), a medium-term rise (8.54% over three months), and a longer-term gain (20.63% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current MBX Biosciences, Inc. Common Stock (MBX) stock price?

MBX Biosciences, Inc. Common Stock (NASDAQ: MBX) stock price is $43.91 in the last trading session. During the trading session, MBX stock reached the peak price of $46.01 while $43.25 was the lowest point it dropped to. The percentage change in MBX stock occurred in the recent session was 2.05% while the dollar amount for the price change in MBX stock was $0.88.

MBX's industry and sector of operation?

The NASDAQ listed MBX is part of Biotechnology industry that operates in the broader Healthcare sector. MBX Biosciences, Inc. Common Stock designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MBX?

No Data

How MBX did perform over past 52-week?

MBX's closing price is 363.19% higher than its 52-week low of $9.63 where as its distance from 52-week high of $46.01 is -4.56%.

How many employees does MBX have?

Number of MBX employees currently stands at 43.

Link for MBX official website?

Official Website of MBX is: https://mbxbio.com

How do I contact MBX?

MBX could be contacted at phone 317 659 0200 and can also be accessed through its website. MBX operates from 11711 N. Meridian Street, Carmel, IN 46032, United States.

How many shares of MBX are traded daily?

MBX stock volume for the day was 660.8K shares. The average number of MBX shares traded daily for last 3 months was 657.1K.

What is the market cap of MBX currently?

The market value of MBX currently stands at $1.48B with its latest stock price at $43.91 and 33.59M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	43
Beta	0.75
Sales or Revenue	N/A
5Y Sales Change%	0%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

MBX Company Profile and Key Details

MBX Biosciences Common Stock

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Company Overview

Earnings & Analyst Outlook

Dividend & Fair Value

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Valuation Metrics